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SUMMARY 
Objectives: Since the risk of multidrug-resistant tuberculosis (MDR-TB) may depend on the 
setting, we aimed to determine the associations of risk factors of MDR-TB across different 
regions.  
Methods: A systematic review and meta-analysis was performed with Pubmed and Embase 
databases. Information was retrieved on 37 pre-defined risk factors of MDR-TB. We 
estimated overall Mantel-Haenszel odds ratio as a measure of the association.  
Results: Factors of previous TB disease and treatment are the most important risk factors 
associated with MDR-TB. There was also a trend towards increased risk of MDR-TB for 
patients 40 years and older, unemployed, lacking health insurance, smear positive, with non-
completion and failure of TB treatment, showing adverse drug reaction, non-adherent, HIV 
positive, with COPD and with M. Tuberculosis Beijing infection. Effect modification by 
geographical area was identified for several risk factors such as male gender, married patients, 
urban domicile, homelessness and history of imprisonment. 
Conclusions: Assessment of risk factors of MDR-TB should be conducted regionally to 
develop the most effective strategy for MDR-TB control. Across all regions, factors 
associated with previous TB disease and treatment are essential risk factors, indicating the 
appropriateness of diagnosis, treatment and monitoring are an important requirements.  
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INTRODUCTION 
According to the World Health Organization (WHO), tuberculosis (TB) remains a global 
problem with an increasing trend of new cases of TB from 6.1 million in 2015 to 6.3 million 
in 2016. 
1
 This global health problem has further worsened in recent years due to the increase 
in multidrug-resistant tuberculosis (MDR-TB, M. tuberculosis resistant to rifampicin and 
isoniazid), with an estimated 490 000 new patients in 2016.
1
 From a health economics 
perspective, MDR-TB is a heavy burden on health care systems with treatment costs 20 times 
higher than the corresponding cost of drug-susceptible TB (DS-TB).
2
 
The occurrence of drug-resistant tuberculosis (DR-TB) is not only determined by timely 
and correct diagnosis, adequate use of anti-TB drugs, patient factors commonly associated 
with drug adherence (beliefs, barriers, behavior), but also determined by microbiological 
factors.
3
 Since spontaneous resistance mutation occurs for isoniazid and rifampicin, a 
combination of several TB-drugs is mandatory to avoid development of drug resistance. 
Although the combination of antibiotics in TB treatment can prevent acquired drug resistance 
to some extent, problems of adverse drug reactions (ADRs), potentially leading to treatment 
failure, remain a challenge worldwide.
4
 
In 2014 WHO formulated globally applicable programmatic management guidelines for 
drug-resistant tuberculosis.
5
 However, several studies reported conflicting results for some 
risk factors of MDR-TB.
6–11
 Thus, identification of the risk factors and possible effect 
modification by region are needed for developing optimal intervention strategies for MDR-
TB control.  
Four systematic reviews and meta-analyses on risk factors for MDR-TB were performed 
prior to our study.
12–15
 The findings of these studies were limited for several reasons. Firstly, 
the focus of the studies was restricted to one region and the geographical effect of the risk 
factors from a global perspective could not be assessed. Secondly, the risk factors were 
  
analysed from a specific perspective, either host- or pathogen related. To support global 
strategies to target MDR-TB effectively, we therefore conducted a comprehensive systematic 
review and meta-analysis in predictive studies to determine risk factors for MDR-TB across 
different regions. These studies had five different perspectives, including host characteristics, 
previous TB disease and treatment, comorbidities, lifestyle and environmental characteristics, 
as well as microbiological aspects. 
  
MATERIAL AND METHODS 
Search strategy and selection criteria 
A systematic review and meta-analysis study following PRISMA guidelines
16
 was 
performed. The study was registered in PROSPERO, number CRD42016038014. We 
included experimental and observational predictive study designs, without language 
restrictions, in which one or multiple risk factors for MDR-TB were analysed during the 
study, from January 1, 2010, to March 26, 2016. We excluded cross-sectional studies, case 
reports, case series, review articles as well as conference abstract papers. 
The study domain was restricted to adult TB-patients, 18 years and older. For cohort 
studies we included adult DS-TB patients as the population at risk, with MDR-TB as the 
outcome. We compared the risk factors of adult DS-TB and MDR-TB patients in included 
case-control studies. DS-TB was defined as fully sensitive of all anti-tuberculosis drugs to the 
Mycobacterium tuberculosis (M.tb) in a TB patient, while MDR-TB was defined as resistance 
to the first-line TB drugs rifampicin and isoniazid, with or without resistance to other first-
line TB drugs. Microbiological verification was needed to confirm resistance type of the 
patients in this study.  
We excluded studies restricted to specific high-risk MDR-TB patient groups, such as TB 
patients with HIV, prior TB treatment, neoplastic disease or diabetes mellitus. We also 
excluded studies that only used clinical or histopathological information for defining the type 
of TB without microbiological confirmation. Six perspectives of risk factors, comprising a list 
of 37 pre-defined variables in total, were analysed. The perspectives and risk factors were 
developed from a conceptual framework of pathogen-host-environment interplay in the 
emerging infectious disease 
17
 as well as previously published studies
12–15
 providing potential 
targets for controlling MDR-TB. The definition criteria for the risk factors can be found in the 
online data supplement Table E1.  
  
The outcome measure was MDR-TB defined as a resistance to the first-line TB drugs 
rifampicin and isoniazid, with or without resistance to other first-line TB drugs. MDR-TB 
status was verified by microbiological test using either phenotyping drug susceptibility test or 
polymerase chain reaction (PCR) based on the identification of mutations linked to resistance 
of M.tb. 
Both Pubmed and Embase databases were used to find potentially eligible articles. We 
developed the search term and strategy together with a medical information specialist at the 
Central Medical Library, University of Groningen, resulting in selecting the following root 
terms : “tuberculosis”,“multiple drug resistant tuberculosis”, “risk factor”, “epidemiologic 
factor”, “risk assessment”, “determinant”, “social determinant of health”, “predictor”. We 
used MeSH terms for the PubMed database and Emtree for the Embase database. Duplicate 
studies from the two databases were removed using the RefWorks® program. The 
comprehensive search terms are provided in the online data supplement Table E2. 
 
Data abstraction and assessment of quality 
Two reviewers (ISP, LDF) independently screened abstracts, full-text articles, and performed 
bias assessments. Disagreements between the two independent reviewers (ISP, LDF) were 
discussed and resolved by a third reviewer (EH). The level of disagreement was calculated 
using a percentage of agreement and reliability, Cohen’s Kappa.18 Data were extracted by the 
first reviewer (ISP) from the included articles, evaluated by the second reviewer (LDF) and 
final evaluation was conducted by the third reviewer (EH). We attempted to contact study 
authors when more data were needed; however, if the information was not received, we 
assumed that data were missing. We conducted a risk of bias assessment using the Risk of 
Bias Assessment Tool for Non-randomized studies which is compatible with the Cochrane 





A dichotomous variable was applied for each factor that was analysed. We pooled all risk 
factors that had a similar definition using Mantel-Haenszel Odds Ratio (mhOR) with a 95% 
confidence interval (95% CI). The significance threshold was set at p-value < 0·05. If data 
about a risk factor were only available in one study, Odds Ratio (OR) instead of mhOR was 
calculated. The level of heterogeneity (I
2
 and p-value) was calculated to identify variation in 
association measures across the studies. We defined considerable heterogeneity as I
2 ≥ 75%20 
and/or a p-value of heterogeneity < 0·05.
21
 If the data were heterogeneous, we applied a 
random effects model to estimate the overall effect size. Furthermore, we performed a 
subgroup analysis to identify sources of heterogeneity. The geographic area of the study was 
used for stratification in subgroup analysis. Additionally, we performed sensitivity analysis 
for risk factors with heterogeneous data that excluded the high potential risk of bias studies, to 
identify the effect size of each risk factor. Heterogeneity level and direction of the effect size 
among the group were considered in defining the effect estimated in the sensitivity analysis. 
We used Review Manager version 5.3 to analyse the effect size of the study. 
  
RESULTS 
The search process found 644 original publications from Pubmed and 764 publications 
from Embase. A total of 1,056 abstracts were screened after duplications were removed, and 
1,036 articles were excluded for several reasons (Figure 1). There were 47 discrepancies 
between the two independent reviewers in the title-abstract screening. The level of agreement 
was 96% (good), and the reliability according to Cohen’s Kappa was 0·78 (good). 
Furthermore, the disagreement arose in seven out of the 117 articles in the full-text screening, 
with a level of agreement of 94% (good), and reliability according to Cohen’s kappa was 0·84 
(good).  
We found 20 studies fulfilling the inclusion criteria from the following continents; Asia 
(14), Africa (2), North America (1), South America (2) and Europe (1). The total number of 
patients included was 20 017, among which 1814 were MDR-TB patients and 18 203 DS-TB 
patients. Study characteristics are shown in Table 1.  
Potential bias was analysed for the 20 included studies. Thirty percent of all included 
studies displayed a high potential for bias in the measurement of exposure. Interview bias, 
recall bias, self-reported data, and unclear definition of the exposure were identified as 
common sources of bias. However, the overall risk of bias was low (see supplementary Fig. 
E1, E2).  
Not all pre-defined perspectives could be analysed due to lack of availability of the data in 
the included articles. We were not able to analyse risk factors from a health services 
perspective. Therefore five of the six different perspectives of risk factors, comprising 29 
specific factors from the included studies, were analysed in this study. Additional data were 
received upon request for one study.
6
 We identified significant risk factors of MDR-TB 
(p<0.05) from four perspectives, namely patient characteristics (i.e. unemployed, lacking 
health insurance coverage, smear positive, mantoux test positive and lung cavity), TB history 
  
and treatment (i.e. previous TB disease, previous TB treatment, non-completion and failure of 
TB treatment, adverse drug reaction, non-BCG vaccination, non-adherence), comorbidity (i.e. 
Chronic Obstructive Pulmonary Disease, COPD) and strain (i.e. M.tb Beijing strain). 
However, several risk factors of MDR-TB showed heterogeneous results (I
2
 ≥ 75% or p-value 
heterogeneity < 0·05), i.e. age 40 years and older, male gender, married patients, lung cavity, 
previous TB disease, previous TB treatment, HIV, known contact with TB patients, low BMI, 
urban domicile, homelessness, and history of imprisonment. The pooled effect estimated for 
all risk factors can be found in Table 2. 
Subgroup analysis was performed for factors with heterogeneous results to identify the 
effect of geographical area. When stratifying patients by setting, homogenous results 
appeared within subgroups for variables of gender, marital status, previous TB disease, 
domicile area, nature of abode, and history of imprisonment status (Fig. 2, 3), while 
heterogeneous results appeared within subgroups for variables of age, BMI, status of lung 
cavity, previous TB treatment, HIV and known contact with TB patients (see supplementary 
Figure E3, E4). 
Subgroup analysis indicated variations dependent on setting for several risk factors of 
MDR-TB, such as male gender, married patients, urban domicile, homelessness, having a 
previous TB disease and a history of imprisonment. For example, pooled effect estimates of 
studies in America (Brazil and USA)
22,23
 showed female patients and unmarried patients were 
more likely to be diagnosed with MDR-TB than DS-TB. On the contrary, effect estimates 
from studies in Western Asia (Iran and Israel)
7,24,25
 revealed that males were more prone to 
MDR-TB and marital status was not a risk factor for MDR-TB in Asia (Fig. 2A, 2B).
26,27
 
Likewise, studies from North America
23
 described a protective effect of MDR-TB for subjects 
who had a history of imprisonment, whereas several Asian studies failed to prove any 




Regarding variables of previous TB disease status and domicile area, we analysed that 
having a previous TB disease remained a significant risk factor of MDR-TB in the pooled 
estimate (p< 0·001; OR 4·42; 95%CI 1·46-13·37). Although risk factors of previous TB 
disease showed heterogeneous result (I
2
: 86%), the forest plot described the same directions 
for a risk factor of MDR-TB in the all subgroups of variable previous TB disease (Fig. 2C). 
On the contrary, the risk factor of urban domicile differed significantly depending on the 
setting, where a Malaysian study indicated a protective effect of urban dwelling (p=0·03; OR 
0·39; 95%CI 0·16-0·93) whereas a study in China showed an increased risk (p= 0·001; OR 
1·77; 95%CI 1·42-2·21) (Fig. 3A).  
Since heterogeneity in several variables, such as age, BMI and status of lung cavity, 
previous TB treatment, HIV, known contact with TB remained high (see Supplementary Fig. 
E3, E4), we therefore conducted a sensitivity analysis of these variables by excluded studies 
with high risk of bias. The studies that were exluded in the sensitivity analysis, i.e. studies 
assessing age (three studies
9,11,28
), lung cavity (five studies
8–10,29,30
), previous TB treatment 
(eight studies
10,11,22,24,26–29
), HIV (six studies
9–11,23,27,30
), known contact with TB (six 
studies
10,11,22,24,26,27
) and BMI (one study
9
). The sensitivity analysis showed being HIV 
positive, previous TB treatment and age 40 years and older to be risk factors of MDR-TB 
(Table 3). However, the variables ‘previous TB treatment’ and ‘lung cavity status’ displayed 
a heterogenous association with the risk of MDR-TB and should therefore be interpreted 
carefully. Regarding previous TB treatment, despite heterogeneity all effect estimates of the 
studies were of the same nature as risk factors of MDR-TB, while the presence of lung cavity 
cannot be interpreted as a risk factor for MDR-TB since effect estimates across studies 
showed conflicting results (supplementary Fig. E4B). 
  
DISCUSSION 
We identified an effect modification by geographic area for several risk factors of MDR-
TB, such as male gender, married patient, urban domicile, homelessness and having a history 
of imprisonment. Our results confirm prior reviews that having a previous TB disease and 
treatment are the most influential risk factors for developing MDR-TB, independent of the 
setting. Furthermore, patients 40 years and older, lacking health insurance, unemployed, non-
adherent, ADRs, with a history of non-completion or failure of TB treatment, without BCG 
vaccination, HIV positive, with COPD, with infection with M. tb Beijing strain, smear and 
mantoux test positivite, show significant risk factors for developing MDR-TB. On the 
contrary, other risk factors identified in prior studies, such as, low education status, non-
Directly Observed Treatment (DOT), diabetes mellitus, cardiovascular diseases, hepatitis, 
known contact with TB patients, smoking, low BMI and daily alcohol intake, did not show a 
clear association with MDR-TB in our study. 
In terms of microbiological aspect, our study was supported by other studies. Beijing M. tb 







 linking the M. tb Beijing genotype strain with a 
history of previous TB treatment and treatment failure. Animal studies have shown Beijing M. 
tb strains to be more virulent with more extensive tissue destruction, rapid outgrowth, and 
increased mortality.
34
 Suggested hypotheses for this association regard differences in cell wall 
structure, leading to suboptimal intracellular drug concentrations, as well as a higher virulence 
per se, resulting in longer persistent infection.
35
 
Regarding comorbidities, it is a matter of debate whether HIV is a risk factor for MDR-TB. 
A previous systematic review showed no association between HIV and primary or secondary 
MDR-TB.
36
 However, our study indicated that HIV is a risk factor for MDR-TB after 
sensitivity analysis was performed. This can be explained by both immune status and drug-
  
related factors. Immunosuppression can lead to reactivation of latent TB, increased risk of re-
infection recurrence due to new M.tb infection and rapid progression to active TB.
37
 
Furthermore, problems relating to drug interactions, overlapping drug toxicities, high pill 
burden, drug malabsorption and immune reconstitution inflammatory syndrome (IRIS) can 
potentially lead to the development of drug resistance and therapeutic failure in co-infected 
TB-HIV patients.
38
 Hence, there is biological plausibility for HIV being a risk factor of MDR-
TB and this finding has been supported by Faustini and co-authors, showing that HIV is 
associated with MDR-TB (OR 3·5; 95% CI 2·48-5·01).
14
  
Another comorbidity, COPD, has also been discussed as a risk factor of MDR-TB. A 
prospective study of pulmonary tuberculosis (PTB) patients aged ≥ 40 years with concomitant 
COPD had an increased risk of developing MDR-TB. 
39
 There is also evidence of an inverse 
relationship; TB patients can develop COPD as a result of long-term damage of structural and 
functional of the lung.
40,41
 In our study, we analysed two case-control studies from Malaysia 
and USA, with 120 MDR-TB patients as cases and 2,186 DS-TB patients as controls. Our 
study indicated that COPD patients were more likely to have MDR-TB than patients without 
COPD, with a pooled estimate 2.5 times higher for COPD patients than non-COPD patients. 
Our study demonstrated that failed TB treatment is a considerable risk factor for MDR-TB. 
Although non-adherence to treatment is believed to be a cause of treatment failure in TB 
patients, a pre-clinical study showed that non-adherence alone was not sufficient for the 
development of MDR-TB, but in-between patient pharmacokinetic variability was 
necessary.
42
 Similarly, a meta-analysis identified pharmacokinetic variability of isoniazid to 
be associated with therapeutic failure and acquired drug resistance.
43
 Another meta-analysis 
analysed genetic factors such as rate of acetylation, where patients who have rapid acetylation 
of isoniazid were more likely to have microbial failure, acquire drug resistance and relapse 
than patients with slow acetylation.
43
 On the other hand, patients with a slow isoniazid 
  
acetylation profile were more prone to hepatotoxicity than patients with a rapid acetylation 
profile.
44
 It is apparent that pharmacogenetics variation plays an important role in therapeutic 
response and ADRs, besides inter-individual variability of pharmacokinetics profile.
44
  
Our study corroborated the results of prior meta-analyses showing that previous TB disease 
and treatment were essential risk factors of MDR-TB, while alcohol abuse and low education 
were not.
12–14
Moreover, meta-analyses in China pointed out pulmonary cavity and living in 
rural area as risk factors of MDR-TB,
12,13
 while studies in Europe showed that male gender, 
homelessness and urban domicile to be risk factors of MDR-TB.
14 As described in the 
aforementioned studies, the impact of risk factors can differ according to geographical area.  
Our study suggests that identifying risk factors of MDR-TB regionally is important in 
developing strategies for MDR-TB control as a result of regional differences in the risk 
factors due to variation of healthcare quality, socio-behavioral and poor living conditions. 
Since unemployment and lack of health insurance coverage are risk factors of MDR-TB in 
our study, government support is crucial to organise universal health coverage that will cover 
not only drug cost but also diagnosis, treatment and monitoring for TB patients. In addition, 
enhancing access to health facilities and laboratories, including qualified drug susceptible 
tests, are required for appropriate diagnosis and treatment as well as for correct surveillance of 
the MDR-TB epidemic. 
The fact that we identified non-adherence, previous and failed TB treatment as 
considerable risk factors of MDR-TB in our study, indicates that variation of adherence, 
pharmacokinetics and pharmacogenetics profile among TB patients is a factor that should be 
considered to avoid development of MDR-TB. Antibiotic stewardship program for drug-
resistant tuberculosis is required to be established at an institution level, specifically in high-
burden areas of TB. The collaborative team should include physicians, pharmacists, 
microbiologists, nurses and administrators, all with a common goal to improve diagnosis, 
  
treatment and monitoring of TB patients. Personalised treatment could be a promising 
approach for controlling MDR-TB, especially in patients at high risk of MDR-TB. 
Therapeutic drug monitoring and intervention with individual non-adherence can be 
implemented as a program to achieve treatment success.
45
 However, since personalised 
treatment needs advanced resources, free consultation of TB experts should be widely 
available for health care providers to make rapid decisions on the management of complex TB 
cases, particularly in an area with limited resources.  
There are several limitations in our study. Firstly, most of our included studies were case-
control studies where recall bias may have occurred. Secondly, not all countries and included 
risk factors could be assessed due to unavailability of data. Thirdly, since the majority of 
studies were predictive studies, the causality of risk factors and outcome should be explored 
further using an appropriate study design. Finally, the power of the study was low for some 
risk factors of MDR-TB, such as non-BCG vaccination and positive Mantoux test. We 
noticed a potential information bias due to missing data in the only included study which 
analysed positive Mantoux test as a risk factor for MDR-TB. The study showed a high 
proportion of participants who had unknown information of Mantoux test results in the MDR-
TB group (58.8%). The multivariate analysis indicated that Mantoux test positivity and non-
BCG vaccine status were not significant risk factors for MDR-TB. (p≥0·05).10,26 Hence, there 
is no clear support of an association of Mantoux test and BCG vaccination with MDR-TB.  
On the other hand, we performed a thorough full-text screening, excluding studies with a 
high level of bias in the sensitivity analysis. We also assessed statistical heterogeneity and 
biological plausibility from the current evidence. Furthermore, we attempted to contact study 
authors to obtain more comprehensive data in our study.  
In conclusion, factors of previous TB disease and treatment are the major risk factors for 
MDR-TB across all settings. Subsequently, we identified patients age 40 years and older, 
  
unemployed, lacking health insurance, smear positive, with a history of non-completion and 
failure of TB treatment, with adverse drug reaction, non-adherent, HIV positive, with COPD 
and with M. Tuberculosis Beijing infection who should be carefully monitored during their 
TB treatment to avoid development of MDR-TB. Equally important, risk factors of MDR-TB 
related to male gender, married patient, urban domicile, homelessness and having a history of 
imprisonment can vary depending on the setting. Therefore, assessment of risk factors of 
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644 records identified through 
Pubmed database searching 
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97 Full-text articles excluded: 
 46 drug-resistant TB were 
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group  
13 conference abstracts  
11 drug susceptibility test were 
not performed 
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 9 Population was restricted to: 
1 HIV 
3 Previous TB treatment  
1 Diabetes mellitus  
4 Suspect Drug resistant TB  
6 cross-sectional studies  
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A. Gender (female vs. male) 
 
 
B. Marital status (unmarried vs. married) 
 
C. Previous TB disease (non-previous TB disease vs. previous TB disease) 
 
Figure 2. Homogeneous effect estimated within the subgroup of gender, marital status and 
previous tuberculosis disease, stratified by area of study. Notes: reference group in each of 
factors: (A) female, (B) unmarried (C) non-previous TB disease; Citation of the studies refers 
to Table 1.  
  
A.  Domicile area (rural vs. urban) 
 
 
B. Nature of abode (non-homelessness vs. homelessness) 
 
 
C. History of imprisonment (non-history of imprisonment vs. history of imprisonment) 
 
 
 Figure 3. Homogeneous effect estimated within the subgroup of domicile area, nature of 
abode and history of imprisonment, stratified by area of study. Notes: reference group in each 
of factors: (A) rural domicile, (B) non-homelessness, (C) non-history of imprisonment 
Citation of the studies refers to Table 1. 
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Risk factors identified 




Pakistan Case-control 2000-2002 50 75 Marital status, gender, non-BCG vaccination, previous 
treatment, smoking, known contact with TB patient 






Case-control 2005-2007 123 116 Gender, non-completion and failure of TB treatment, 
HIV 




Iran Case-control 2002-2005 48 234 Gender, previous treatment, smear positivity, smoking, 
known contact with TB patient 




India Case-control 2002-2007 30 117 Gender, lung cavity, HIV 
Chuchottawo




Thailand Case-control 2007-2013 145 145 Age 40 years and older, gender, non-completion and 
failure of TB treatment, CVD, DM, HIV, low BMI 




Brazil Case-control 2000-2004 12 36 Employment status, gender, previous treatment, smear 
positivity, DM, HIV, known contact with TB patient, 
daily alcohol consumption 






Case-control 2005-2006 56 304 Age 40 years and older, employment status, gender, 
previous treatment, HIV, known contact with TB 
patient, daily alcohol consumption 
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Case-control 1995-2001 15 1977 Marital status, gender, previous TB disease, COPD, 
HIV, history of imprisonment, history homeless, daily 
alcohol consumption 




Malaysia Case-control 2010-2014 105 209 Gender, previous treatment, COPD, Mantoux test 
positivity, lung cavity, HIV, history of imprisonment, 
smoking, history of homeless, known contact with TB 
patient, daily alcohol consumption 




Colombia Case-control 2007-2008 76 84 M. tb Beijing genotype strain 




Israel Case-control 2002-2009 44 508 Gender, DOT, non-completion and failure of TB 
treatment, previous TB disease, hepatitis, lung cavity, 
HIV 




China Cohort 2008-2010 17
 
1609 Age 40 years and older, gender, ADRs, previous 
treatment, low BMI 




Vietnam Case-control 2007-2009 22 298 Gender, HIV smoking, M. tb Beijing genotype strain 




China Case-control 2007-2009 100 97 Non-coverage health insurance, gender, previous 
treatment, lung cavity, known contact with TB patient, 





Malaysia Case-control 2013-2014 30 120 Marital status, gender, non-adherence, higher 
education, previous treatment, smear positive, DM, 
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HIV, history of imprisonment, smoking, urban area, 
known contact with TB patient, daily alcohol 
consumption 




Israel Case-control 1999-2000 207 3107 Gender, previous treatment, smear positivity, HIV, 





England Case-control 1982-2004 42 84 Gender, previous TB disease, smear positivity, known 
contact with TB patient 




China Case-control 2000-2006 333 7018 Gender, previous treatment, smear positivity, lung 
cavity, urban area 




India Case-control 2009 184 56 Gender, previous TB disease, lung cavity, HIV 




China Case-control 2004-2005 175 2009 Age 40 years and older, gender, previous TB treatment 
Notes: MDR-TB: multidrug-resistant tuberculosis; DS-TB: drug-susceptible tuberculosis; BCG: Bacille Calmette-Guérin; HIV: human 
immunodeficiency virus; CVD: cardiovascular; DM: diabetes mellitus; BMI: body mass index; COPD: chronic obstructive pulmonary disease; 
M.tb: Mycobacterium tuberculosis; DOT: directly observed treatment; ADRs: adverse drug reactions. 
 29 
 
Table 2. Effect estimates for risk factors of Multidrug-Resistant Tuberculosis (MDR-TB) 
 
Risk factors Number of 
Studies 
Participants Effect Estimated 







Age 40 years and older  4
9,11,28,48












 150 1·69 (0·73-3·87) n/a 
Unemployment 2
11,22
 408 3·00 (1·69-5·30)
*† 
69% (0·07) 














 11 161 1·72 (1·40-2·12)
*†
 41% (0·13) 
Mantoux test positive 1
10
 103 3·38 (1·45-7·89)
†
 n/a 
Lung cavity  7
7–10,29,30,49
 8825 1·92 (1·02-3·62)
†
 89% (< 0·001)
†
 
TB history & treatment 




 2907 4·42 (1·46-13·37)
†
 86% (< 0·001)
†
 




 15 657 7·24 (4·06-12·89)
†













 552 1·36 (0·47-3·95) n/a 














 150 4·50 (1·71-11·82)
†
 n/a 
Disease or comorbidity 
HIV positive 11
6–11,23,25,27,30,46





Diabetes mellitus  4
9,10,22,27





 290 0·75 (0·36-1·58) n/a 
COPD  2
10,23





 552 0·42 (0·13-1·40) n/a 
Life style& Environmental 









 1189 0·90 (0·66-1·22)
* 
21% (0·28) 
Low BMI**  2
9,48

















 2306 2·73 (0·18-40·95) 87% (0·006)
†
 
History of imprisonment 4
10,23,25,27




Beijing strain  3
6,47,49
 665 5·58 (1·66-18·76)
 *†
 66% (0·05) 
Notes: * Fixed effect model; 
†
Significant value (p< 0.05); 
‡
including non-cure, non-completion, default and 
failure treatment; ** Body Mass Index (BMI) < 18 kg/m
2
; n/a : not applicable; COPD: Chronic obstructive 








Table 3. Sensitivity analysis of heterogeneous’ factors. 



















1 Age 40 years and 
older 

























3 Presence of 
previous TB 
treatment 





























5 Known contact 
























Significant value; Low body mass index (BMI) : BMI < 18 kg/m
2
; 95%CI : 95% 
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Table E1. Exposure criteria of systematic review and meta-analysis study on risk factors of 
multidrug-resistant tuberculosis 
 
No Perspectives Exposure/Risk factor Operational Definition 
1 Patients 
characteristics 
Age Age of the participants, divided between < 40 and ≥ 
40 years old 
Gender Male or female 
Level of education Categorized as lower education (below diploma 
level or non-education) and higher education 
(diploma, bachelor, master or doctoral degree) 
Knowledge of MDR-TB Participants who can explain the basic 
understanding of tuberculosis and MDR-TB 
correctly, i.e., signs, symptoms, process of TB 
spreading, the definition of MDR-TB and awareness 
of the long treatment duration is identified as good 
knowledge. 
Occupation Occupation of the participants 
Marital status Married or unmarried 
Lack of health insurance Participants who have no health insurance coverage  
2 Tuberculosis 
(TB) history and 
treatment 
Previous treatment Participants who have received at least one month of 
anti-Tb drugs in the past, regardless of their 
treatment outcome. 
Previous TB disease Participants with a history of previous TB, 
regardless of treatment status 
Non-completion and 
failure of TB treatment 
Participants who have one of the criteria below : 
 non-completion: participants who discontinued/ 
stopped treatment before defined period of 
treatment, OR 
 non-cure or failure treatment: a patient who is 
sputum smear or sputum culture positive at five 
months or later after the initiation of anti TB 
treatment, OR 
 default: participants who have interrupted TB 
treatment for two or more consecutive months 
Fixed Dose Combination 
(FDC) 
Participants treated with FDC rather than multiple 
single anti-tuberculosis drug use 
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Route of administration Intravenous versus oral treatment 
Adverse drug reactions 
(ADRs) 




Participants who had a previous BCG-vaccination. 
Non-adherence Participants who completed the duration of 
treatment, who however took less than 90% of the 
prescribed anti-tuberculosis drug without clinical 
reasons, such as adverse drug reaction or drug 
interaction. 
3 Comorbidities Human 
Immunodeficiency Virus 
(HIV) 
Clinically or lab-confirmed diagnosis of HIV 
Diabetes mellitus (DM) Diagnostic criteria of fasting plasma glucose ≥ 7.0 
mmol/l (126 mg/dl) or 2-h plasma glucose ≥ 11.1 





Clinically confirmed diagnosis of COPD, including 
emphysema, chronic bronchitis, refractory (non-
reversible, asthma, and bronchiectasis). 
Cardiovascular diseases 
(CVD) 
Includes diagnoses such as previous heart attack, 
ischemic stroke, heart failure, arrhythmia, and health 
valve disease 
Hepatitis Any viral hepatitis with laboratory confirmation or 
stated in medical records by a medical doctor. 
Liver diseases Any diagnosis of liver disease and/or three times 
elevated the normal value of Alanine Transaminase 
(ALT) in the blood (ref 7-56 unit/L) 
Lung cavity Presence of lung cavity on chest x-ray 
Hypoalbuminea Plasma albumin < 35 g/dL 
Sputum smear positivity Visible M. tb in the sputum during microscopy 
(Ziehl-Neehlsen or auramine stain)  
Low Body Mass Index 
(BMI) 
BMI < 18 Kg/m
2 
Positive Mantoux test A positive tuberculin skin test, defined according to 
a medical doctor’s interpretation after dermal 
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injection of protein derivative of tubercle bacillus, 




4 Lifestyle and 
Environmental 
Smoking Including former and current smoking habit, 
regardless of duration 
Known contact with TB 
patient 
Known previous contact with a patient diagnosed 
with contagious TB 
Daily alcohol 
consumption 
Participants who consume alcohol on a daily basis 
Nature of abode It is divided into homelessness and non-
homelessness. Homelessness is defined as 
participants who have a previous or current history 
of homelessness 
History of imprisonment Participants who are currently imprisoned or have a 
previous history of imprisonment. 
Domicile area Domicile area of the participant. It is divided into 
two categories, i.e. urban domicile and rural 
domicile. 
Room spaces Total number of rooms in the household 
5 Microbiology Beijing strain M. tb type Beijing strain 
6 Health services Accessibility of health 
facility 
Distance and travel time to the health facility 
Drug supply Availability of anti-tuberculosis drugs in the health 
facility  
Low-quality medicines Low quality of medicine refers to counterfeit and/or 
poor quality anti-TB drugs based on physical and 














1 Pubmed (((("Tuberculosis, Multidrug-Resistant"[Mesh] OR multidrug resistant 
tuberculosis[tiab] OR mdr tb[tiab] OR mdr tuberculosis[tiab] OR mdr-
tb[tiab] OR multi drug resistant tuberculosis[tiab] OR multi-drug 
resistant tuberculosis[tiab] OR multiple drug resistant 
tuberculosis[tiab])) AND ("Risk Factors"[Mesh] OR "Epidemiologic 
Factors"[Mesh] OR predictor*[tiab] OR determinant*[tiab] OR risk 
factor*[tiab] OR epidemiologic factor*[tiab]))) NOT ("Cross-
Sectional Studies"[Mesh] OR cross-sectional [tiab] OR cross sectional 
[tiab] OR crosssectional [tiab]) 
Filters:Publication date from 2006/01/01 to 2016/03/26 
2 Embase # 1  
'risk assessment'/exp OR 'risk assessment' OR 'risk factor'/exp OR 
'risk factor' OR 'predictor variable'/exp OR 'predictor variable' OR 
'social determinants of health'/exp OR 'social determinants of health' 
OR 'risk factor':ab,ti OR 'risk factors':ab,ti OR 'epidemiologic 
factor':ab,ti OR 'epidemiologic factors':ab,ti OR 'predictor*':ab,ti OR 
'determinant*':ab,ti 
#2 
'multidrug resistant tuberculosis'/exp OR 'multidrug resistant 
tuberculosis':ab,ti OR 'mdr tb':ab,ti OR 'multi-drug resistant 
tuberculosis':ab,ti OR 'mdr-tb':ab,ti OR 'mdr tuberculosis':ab,ti OR 
'multi drug resistant tuberculosis':ab,ti OR 'multiple drug resistant 
tuberculosis':ab,ti 
#3 
'cross-sectional study'/exp OR 'cross-sectional study' OR 'cross 
sectional':ab,ti OR 'çross-sectional':ab,ti OR 'crosssectional':ab,ti 
















Figure E2. Risk of bias summary: review authors’ judgment about each risk of bias item for each included study. 
Notes: Green (+) shows low risk of bias, yellow (?) shows unclear risk of bias, and red (-) shows high potential risk of bias. Notes: Citation of the 









A. Age (˂ 40 years vs. ≥ 40 years) 
 
 
B. HIV (non-HIV vs. HIV) 
 
 
C. Previous TB treatment (non-previous TB treatment vs. previous TB treatment) 
 
Figure E3. Heterogeneous effect estimated in several risk factors of MDR-TB stratified by 
area of study. Notes: TB: tuberculosis; reference group in each factor: (A) age less than 40 




A. BMI (BMI≥ 18 Kg/m2 vs. BMI ˂ 18 Kg/m2) 
 
 
B. Lung Cavity (non-lung cavity vs. lung cavity) 
 
C. Known contact with TB patient (no contact vs. contact) 
 
Figure E4. Heterogeneous effect estimated in several risk factors of MDR-TB. Notes: TB: 
tuberculosis; reference groups in each factor: (A) BMI ≥ 18 Kg/m2, (B) non-lung cavity, (C) 
No contact with TB patient; BMI: body mass index; Citation of the studies refers to Table 1. 
 
